Major and minor salivary gland cancers: A multicenter retrospective study.


Journal

Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541

Informations de publication

Date de publication:
07 2023
Historique:
revised: 15 03 2023
received: 24 11 2022
accepted: 10 04 2023
medline: 8 6 2023
pubmed: 21 4 2023
entrez: 21 04 2023
Statut: ppublish

Résumé

Most of the studies on salivary gland cancers are limited for various reasons such as being single-center, small number of patients, including only major or minor SGCs, or only including epidemiological data. A total of 37 medical oncology clinics from different regions of Turkey participated in this retrospective-multicenter study. The analyzed data included clinical and demographical features, primary treatment, metastasis localizations, and treatments and includes certain pathologic features. The study included data from a total of 443 SGCs. 56.7% was in major salivary glands and 43.3% was in minor salivary glands. Distant metastasis in the major SGCs was statistically significantly more common than in the minor SGCs, locoregional recurrence was statistically significantly more common in the minor SGCs than in the major SGCs (p = 0.003). Epidemiological information, metastasis and recurrence patterns, treatment modalities, and survival analysis of the patients over 20 years of follow-up are presented.

Sections du résumé

BACKGROUND
Most of the studies on salivary gland cancers are limited for various reasons such as being single-center, small number of patients, including only major or minor SGCs, or only including epidemiological data.
METHODS
A total of 37 medical oncology clinics from different regions of Turkey participated in this retrospective-multicenter study. The analyzed data included clinical and demographical features, primary treatment, metastasis localizations, and treatments and includes certain pathologic features.
RESULTS
The study included data from a total of 443 SGCs. 56.7% was in major salivary glands and 43.3% was in minor salivary glands. Distant metastasis in the major SGCs was statistically significantly more common than in the minor SGCs, locoregional recurrence was statistically significantly more common in the minor SGCs than in the major SGCs (p = 0.003).
CONCLUSIONS
Epidemiological information, metastasis and recurrence patterns, treatment modalities, and survival analysis of the patients over 20 years of follow-up are presented.

Identifiants

pubmed: 37084179
doi: 10.1002/hed.27376
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1643-1653

Informations de copyright

© 2023 The Authors. Head & Neck published by Wiley Periodicals LLC.

Références

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
Hay AJ, Migliacci J, Karassawa Zanoni D, McGill M, Patel S, Ganly I. Minor salivary gland tumors of the head and neck-Memorial Sloan Kettering experience: incidence and outcomes by site and histological type. Cancer. 2019;125(19):3354-3366.
Skálová A, Hyrcza MD, Leivo I. Update from the 5th edition of the World Health Organization classification of head and neck tumors: Salivary glands. Head Neck Pathol. 2022;16(1):40-53.
Fu JY, Wu CX, Shen SK, Zheng Y, Zhang CP, Zhang ZY. Salivary gland carcinoma in Shanghai (2003-2012): an epidemiological study of incidence, site and pathology. BMC Cancer. 2019;19(1):350.
Nachtsheim L, Mayer M, Meyer MF, et al. Incidence and clinical outcome of primary carcinomas of the major salivary glands: 10-year data from a population-based state cancer registry in Germany. J Cancer Res Clin Oncol. 2022; in press.
Sousa LG, Wang K, Torman D, et al. Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. Cancer. 2022;128(3):509-518.
Carlson ER, Schlieve T. Salivary gland malignancies. Oral Maxillofac Surg Clin North Am. 2019;31(1):125-144.
Benchetrit L, Mehra S, Mahajan A, Rahmati RW, Judson BL, Edwards HA. Major salivary gland cancer with distant metastasis upon presentation: patterns, outcomes, and imaging implications. Otolaryngol Head Neck Surg. 2022;167(2):305-315.
Alsanie I, Rajab S, Cottom H, et al. Distribution and frequency of salivary gland tumours: an international multicenter study. Head Neck Pathol. 2022;16(4):1043-1054.
Mahomed Y, Meer S. Primary epithelial minor salivary gland tumors in South Africa: a 20-year review. Head Neck Pathol. 2020;14(3):715-723.
Coca-Pelaz A, Rodrigo JP, Bradley PJ, et al. Adenoid cystic carcinoma of the head and neck-An update. Oral Oncol. 2015;51(7):652-661.
Son E, Panwar A, Mosher CH, Lydiatt D. Cancers of the major salivary gland. J Oncol Pract. 2018;14(2):99-108.
Lee SY, Shin HA, Rho KJ, Chung HJ, Kim SH, Choi EC. Characteristics, management of the neck, and oncological outcomes of malignant minor salivary gland tumours in the oral and sinonasal regions. Br J Oral Maxillofac Surg. 2013;51(7):e142-e147.
Abdel Razek AAK, Mukherji SK. Imaging of minor salivary glands. Neuroimaging Clin N Am. 2018;28(2):295-302.
Copelli C, Bianchi B, Ferrari S, Ferri A, Sesenna E. Malignant tumors of intraoral minor salivary glands. Oral Oncol. 2008;44(7):658-663.
Pires FR, Pringle GA, de Almeida OP, Chen SY. Intra-oral minor salivary gland tumors: a clinicopathological study of 546 cases. Oral Oncol. 2007;43(5):463-470.
Nam SJ, Roh JL, Cho KJ, Choi SH, Nam SY, Kim SY. Risk factors and survival associated with distant metastasis in patients with carcinoma of the salivary gland. Ann Surg Oncol. 2016;23(13):4376-4383.
Ali S, Bryant R, Palmer FL, et al. Distant metastases in patients with carcinoma of the major salivary glands. Ann Surg Oncol. 2015;22(12):4014-4019.
Mimica X, McGill M, Hay A, et al. Distant metastasis of salivary gland cancer: incidence, management, and outcomes. Cancer. 2020;126(10):2153-2162.
Turchan WT, Korpics MC, Rooney M, Koshy M, Spiotto MT. Impact of anatomic site of distant metastasis on survival in salivary gland cancers. Head Neck. 2021;43(9):2589-2601.
Young A, Okuyemi OT. Malignant Salivary Gland Tumors. StatPearls; 2022.
Lombardi D, McGurk M, Vander Poorten V, et al. Surgical treatment of salivary malignant tumors. Oral Oncol. 2017;65:102-113.
Rosenberg L, Weissler M, Hayes DN, et al. Concurrent chemoradiotherapy for locoregionally advanced salivary gland malignancies. Head Neck. 2012;34(6):872-876.
Gebhardt BJ, Ohr JP, Ferris RL, et al. Concurrent chemoradiotherapy in the adjuvant treatment of high-risk primary salivary gland malignancies. Am J Clin Oncol. 2018;41(9):888-893.
Park GC, Roh JL, Cho KJ, et al. Incidence and risk factors of late recurrence in patients with salivary gland cancer. Clin Otolaryngol. 2017;42(2):416-424.
Tchekmedyian V. Salivary gland cancers. Hematol Oncol Clin North Am. 2021;35(5):973-990.
Liu Y, Mi Y, Zhang L, Gong Q, Jiang T. Prognostic analysis and establishment of a nomogram in patients with myoepithelial carcinoma of the salivary gland: a population-based study. Laryngosc Investig Otolaryngol. 2022;7(1):125-134.
Boon E, Bel M, van Boxtel W, et al. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands. Int J Cancer. 2018;143(4):758-766.
Amit M, Binenbaum Y, Sharma K, et al. Analysis of failure in patients with adenoid cystic carcinoma of the head and neck.; An International collaborative study. Head Neck. 2014;36(7):998-1004.
Ali S, Palmer FL, Yu C, et al. A predictive nomogram for recurrence of carcinoma of the major salivary glands. JAMA Otolaryngol Head Neck Surg. 2013;139(7):698-705.
Terhaard CH, Lubsen H, Van der Tweel I, et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck. 2004;26(8):681-692; discussion 692-683, 693.
Jia MQ, Gao M, Ye P, et al. Survival outcome of salivary gland carcinoma: a 50-year retrospective study with long-term follow-up. J Oral Maxillofac Surg. 2022;80:2003-2014.
Hosni A, Huang SH, Goldstein D, et al. Outcomes and prognostic factors for major salivary gland carcinoma following postoperative radiotherapy. Oral Oncol. 2016;54:75-80.
Szewczyk M, Golusiński P, Pazdrowski J, et al. Patterns of treatment failure in salivary gland cancers. Rep Pract Oncol Radiother. 2018;23(4):260-265.
Kim HR, Lee SJ, Park S, et al. A single-arm, prospective, phase II study of cisplatin plus weekly docetaxel as first-line therapy in patients with metastatic or recurrent Salivary gland cancer. Cancer Res Treat. 2022;54(3):719-727.
Witte HM, Gebauer N, Lappöhn D, et al. Prognostic impact of PD-L1 expression in malignant salivary gland tumors as assessed by established scoring criteria: tumor proportion score (TPS), combined positivity score (CPS), and immune cell (IC) infiltrate. Cancers (Basel). 2020;12(4):873.
Guazzo E, Cooper C, Wilkinson L, et al. Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma. Head Neck. 2021;43(3):768-777.
Steiniche T, Ladekarl M, Georgsen JB, et al. Association of programmed death ligand 1 expression with prognosis among patients with ten uncommon advanced cancers. Future Sci OA. 2020;6(8):FSO616.
Weaver AN, Lakritz S, Mandair D, et al. A molecular guide to systemic therapy in salivary gland carcinoma. Head Neck. 2023;45:1315-1326.

Auteurs

Muhammet Bekir Hacioglu (MB)

Department of Medical Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey.

Bulent Erdogan (B)

Department of Medical Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey.

Murat Bardakcı (M)

Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey.

Efnan Algın (E)

Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey.

Burcu Gulbagcı (B)

Department of Medical Oncology, Faculty of Medicine, Sakarya University, Sakarya, Turkey.

Ilhan Hacibekiroglu (I)

Department of Medical Oncology, Faculty of Medicine, Sakarya University, Sakarya, Turkey.

Jamshid Hamdard (J)

Department of Medical Oncology, Faculty of Medicine, Medipol University, İstanbul, Turkey.

Omer Fatih Olmez (OF)

Department of Medical Oncology, Faculty of Medicine, Medipol University, İstanbul, Turkey.

Hadi Akkus (H)

Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkey.

Berna Oksuzoglu (B)

Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkey.

Sema Sezgin Goksu (SS)

Department of Medical Oncology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.

Shute Ailia Dae (SA)

Department of Medical Oncology, Faculty of Adana Medicine, Baskent University, Adana, Turkey.

Ahmet Taner Sumbul (AT)

Department of Medical Oncology, Faculty of Adana Medicine, Baskent University, Adana, Turkey.

Muzaffer Ugraklı (M)

Department of Medical Oncology, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.

Mustafa Karaagac (M)

Department of Medical Oncology, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.

Elif Sahin (E)

Department of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey.

Devrim Cabuk (D)

Department of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey.

Ozden Ozer (O)

Department of Medical Oncology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.

Tugba Yavuzsen (T)

Department of Medical Oncology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.

Rukiye Arıkan (R)

Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey.

Osman Köstek (O)

Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey.

Muhammed Mustafa Atcı (MM)

Department of Medical Oncology, Prof. Dr. Cemil Tascıoglu City Hospital, Istanbul, Turkey.

Abdullah Sakin (A)

Department of Medical Oncology, Prof. Dr. Cemil Tascıoglu City Hospital, Istanbul, Turkey.

Adem Deligonul (A)

Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey.

Duygu Bayır (D)

Department of Medical Oncology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.

Murat Dincer (M)

Department of Medical Oncology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.

Oktay Unsal (O)

Department of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey.

Ozan Yazıcı (O)

Department of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey.

Esra Zeynelgil (E)

Department of Medical Oncology, Diskapi Yıldırım Beyazıt Education and Research Hospital, Ankara, Turkey.

Ahmet Gulmez (A)

Department of Medical Oncology, Faculty of Medicine, Inonu University, Malatya, Turkey.

Hakan Harputluoglu (H)

Department of Medical Oncology, Faculty of Medicine, Inonu University, Malatya, Turkey.

Cihan Erol (C)

Department of Medical Oncology, Faculty of Medicine, Ankara Yıldırım Beyazit University, Ankara, Turkey.

Mehmet Ali Nahit Sendur (MAN)

Department of Medical Oncology, Faculty of Medicine, Ankara Yıldırım Beyazit University, Ankara, Turkey.

Aydin Aytekin (A)

Department of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey.

Baran Akagunduz (B)

Department of Medical Oncology, Mengucek Gazi Education and Research Hospital, Erzincan Binali Yıldırım University, Erzincan, Turkey.

Irem Oner (I)

Department of Medical Oncology, Konya City Hospital, Konya, Turkey.

Ozlem Er (O)

Department of Medical Oncology, Maslak Hospital, Acıbadem MAA University, Istanbul, Turkey.

Bugra Oztosun (B)

Department of Medical Oncology, Goztepe Education and Research Hospital, Medeniyet University, Istanbul, Turkey.

Mahmut Gumus (M)

Department of Medical Oncology, Goztepe Education and Research Hospital, Medeniyet University, Istanbul, Turkey.

Fatih Selçukbiricik (F)

Department of Medical Oncology, Koc University Hospital, Istanbul, Turkey.

Musa Baris Aykan (MB)

Department of Medical Oncology, Ankara Gulhane Education and Research Hospital, Ankara, Turkey.

Nuri Karadurmus (N)

Department of Medical Oncology, Ankara Gulhane Education and Research Hospital, Ankara, Turkey.

Ezgi Degerli (E)

Department of Medical Oncology, Faculty of Medicine, Cerrahpasa University, Istanbul, Turkey.

Nebi Serkan Demirci (NS)

Department of Medical Oncology, Faculty of Medicine, Cerrahpasa University, Istanbul, Turkey.

Esma Turkmen (E)

Department of Medical Oncology, Derince Education and Research Hospital, Kocaeli, Turkey.

Teoman Şakalar (T)

Department of Medical Oncology, Kahramanmaras Necip Fazıl City Hospital, Kahramanmaras, Turkey.

Saban Secmeler (S)

Department of Medical Oncology, Sanlıurfa Mehmet Akif İnan Education and Research Hospital, Şanlıurfa, Turkey.

Ozgur Tanrıverdi (O)

Department of Medical Oncology, Faculty of Medicine, Mugla Sıtkı Kocman University, Mugla, Turkey.

Ali Alkan (A)

Department of Medical Oncology, Faculty of Medicine, Mugla Sıtkı Kocman University, Mugla, Turkey.

Yasemin Kemal (Y)

Department of Medical Oncology, Faculty of Medicine, Altınbas University, Samsun, Turkey.

Ibrahim Cil (I)

Department of Medical Oncology, Istanbul Umraniye Education and Research Hospital, Istanbul, Turkey.

Caglar Unal (C)

Department of Medical Oncology, Gayrettepe Florence Nightingale Hospital, Istanbul Bilim University, Istanbul, Turkey.

Yakup Iriagaç (Y)

Department of Medical Oncology, Faculty of Medicine, Tekirdag Namık Kemal University, Tekirdag, Turkey.

Ozkan Alan (O)

Department of Medical Oncology, Tekirdag City Hospital, Tekirdag, Turkey.

Sevinc Balli (S)

Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey.

Yuksel Urun (Y)

Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey.

Erkan Ozcan (E)

Department of Medical Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey.

Nazım Serdar Turhal (NS)

Department of Medical Oncology, Anadolu Medical Center, Kocaeli, Turkey.

Irfan Cicin (I)

Department of Medical Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH